Medtronic Reports Strong Fiscal 2025 Revenue Growth Plans Diabetes Spin-Off

Medtronic reported strong fiscal year 2025 results with $8.9 billion in revenue and a 67% GAAP EPS increase, announcing plans to spin off its Diabetes business within 18 months to unlock value and pursue independent growth. The company also raised its dividend to $0.71 per share, marking 48 consecutive years of increases, and forecasted about 5% organic revenue growth for fiscal 2026. MEDIROM Healthcare Technologies experienced a 22% revenue increase to $52.7 million in 2024, driven mainly by growth in its Relaxation Salon Segment, alongside a 20% rise in net income supported by cost management and strategic investments in health tech products like the MOTHER Bracelet. The company completed a $5 million capital raise and secured additional financing to support expansion in digital preventative healthcare. MedX Holdings reported record Q1 2025 revenue, more than tripling year-over-year due to retail expansion, strategic acquisitions, and increased consumer demand, while launching an AI-driven commerce initiative and raising $10 million in convertible notes to fund growth. Together, these companies illustrate strong financial performances and strategic moves in medical technology, healthcare services, and retail innovation sectors.